Synopsis
Distinguish intestinal or urinary carriage from invasive vancomycin-resistant enterococcal disease, obtain cultures and source control, select species- and susceptibility-directed therapy, and contain healthcare transmission without ineffective decolonisation.
- Enterococci normally colonise the bowel. VRE or glycopeptide-resistant enterococci are usually E. faecium carrying vanA or vanB, although other species and intrinsic resistance occur.
- A positive rectal screen, stool culture, chronic wound or asymptomatic catheter urine usually represents carriage and does not require systemic antibiotic treatment.
- Bloodstream isolation is always significant. Obtain cultures before treatment when safe, repeat until clearance and identify central-line, biliary, urinary, abdominal, valve or prosthetic sources.
- Species and full susceptibility matter: vancomycin resistance does not always imply ampicillin resistance, particularly in E. faecalis, so a susceptible narrow beta-lactam may remain preferable.
- Linezolid 600 mg orally or intravenously every 12 hours is a standard active option for invasive VRE; oral bioavailability permits dose-equivalent step-down when appropriate.
- High-dose daptomycin 10 to 12 mg/kg intravenously every 24 hours is an off-label specialist option for VRE bloodstream and endovascular disease, often with beta-lactam synergy in persistent or endocardial infection.
- Daptomycin must not be used for pneumonia, while tigecycline should not be relied upon for bloodstream or urinary infection because serum and urinary exposure are inadequate.
- Use standard plus IPC-directed contact precautions, single-room or cohort placement, dedicated equipment, environmental cleaning and transfer alerts; there is no established antibiotic decolonisation regimen.
Key red flags
Persistent blood-culture positivity beyond 48 to 72 hours on active therapy suggests retained line, undrained abdominal source, infected thrombus, endocarditis or inadequate exposure.
New murmur, heart failure, conduction abnormality, embolic lesion or prosthetic valve with VRE bacteraemia requires urgent echocardiography and endocarditis-team review.
Severe abdominal pain, peritonism, biliary obstruction or postoperative leak needs urgent imaging and source control; antibiotics alone will not sterilise ongoing contamination.
Thrombocytopenia, anaemia, neuropathy, lactic acidosis or serotonergic toxicity can limit linezolid, particularly during prolonged courses.
Muscle pain, creatine-kinase rise, renal deterioration or new respiratory symptoms during daptomycin requires toxicity review; daptomycin is inactive in pneumonia.
VanA or VanB detection in a high-risk ward, clustering of cases or inter-facility transfer should trigger immediate IPC communication and outbreak assessment.
Fever, rigors, hypotension or organ dysfunction with VRE in blood is invasive disease, often arising from a line or gastrointestinal source.
Investigation priorities
Confirm invasive infection, evaluate sepsis and provide the clearance date that informs duration.
Management branches
VRE is reported from screening, urine, wound, drain or another clinical specimen.
- Examine for local inflammation and systemic illness, identify the specimen quality and ask whether another organism or non-infectious cause better explains the presentation.
- Do not treat a rectal screen, asymptomatic bacteriuria or colonised wound; remove unnecessary urinary or vascular devices and improve wound containment.
- Obtain blood cultures and deep source specimens before therapy when fever, sepsis, sterile-site disease or a high-risk source is present.
- Alert IPC to arrange precautions, screening and communication independently of whether antimicrobial treatment is indicated.